BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 22626996)

  • 21. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
    Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH
    Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of circulating cancer cells by reverse transcription-polymerase chain reaction for uroplakin II in peripheral blood of patients with urothelial cancer.
    Lu JJ; Kakehi Y; Takahashi T; Wu XX; Yuasa T; Yoshiki T; Okada Y; Terachi T; Ogawa O
    Clin Cancer Res; 2000 Aug; 6(8):3166-71. PubMed ID: 10955799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder.
    Degtyar P; Neulander E; Zirkin H; Yusim I; Douvdevani A; Mermershtain W; Kaneti J; Manor E
    Urology; 2004 Feb; 63(2):398-401. PubMed ID: 14972510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression.
    Quentin T; Schlott T; Korabiowska M; Käthei N; Zöller G; Glaser F; Kunze E
    Anticancer Res; 2004; 24(5A):2745-56. PubMed ID: 15517881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Urinary cytokeratin 20 mRNA expression has the potential to predict recurrence in superficial transitional cell carcinoma of the bladder.
    Christoph F; Weikert S; Wolff I; Schostak M; Tabiti K; Müller M; Miller K; Schrader M
    Cancer Lett; 2007 Jan; 245(1-2):121-6. PubMed ID: 16473461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder.
    Shariat SF; Matsumoto K; Casella R; Jian W; Lerner SP
    Eur Urol; 2005 Jul; 48(1):69-76. PubMed ID: 15967254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of hepatoma-up-regulated protein expression in patients with urinary bladder transitional cell carcinoma.
    Huang YL; Chiu AW; Huan SK; Wang YC; Ju JP; Lu CL
    Anticancer Res; 2003; 23(3B):2729-33. PubMed ID: 12894566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urinary insulin-like growth factor 2 identifies the presence of urothelial carcinoma of the bladder.
    Watson JA; Burling K; Fitzpatrick P; Kay E; Kelly J; Fitzpatrick JM; Dervan PA; McCann A
    BJU Int; 2009 Mar; 103(5):694-7. PubMed ID: 19040529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma.
    Moussa M; Omran Z; Nosseir M; Lotfy A; Swellam T
    APMIS; 2009 Jan; 117(1):45-52. PubMed ID: 19161536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Expression of melanoma antigen gene in urinary transitional cell carcinomas].
    Geng L; Yu LZ; Du P; Ma M; Na YQ
    Zhonghua Wai Ke Za Zhi; 2005 May; 43(10):667-71. PubMed ID: 16008943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular staging of bladder cancer with RT-PCR assay for CK20 in peripheral blood, bone marrow and lymph nodes: comparison with standard histological staging.
    Ribal MJ; Mengual L; Marín M; Algaba F; Ars E; Fernández PL; Oliva R; Villavicencio H; Alcaraz A
    Anticancer Res; 2006; 26(1A):411-9. PubMed ID: 16475726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression and clinical significance of Centrosomal protein 55 (CEP55) in human urinary bladder transitional cell carcinoma.
    Singh PK; Srivastava AK; Rath SK; Dalela D; Goel MM; Bhatt ML
    Immunobiology; 2015 Jan; 220(1):103-8. PubMed ID: 25178936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma.
    Shi B; Laudon V; Yu S; Dong D; Zhu Y; Xu Z
    Urol Int; 2008; 81(3):320-4. PubMed ID: 18931551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria.
    O'Sullivan P; Sharples K; Dalphin M; Davidson P; Gilling P; Cambridge L; Harvey J; Toro T; Giles N; Luxmanan C; Alves CF; Yoon HS; Hinder V; Masters J; Kennedy-Smith A; Beaven T; Guilford PJ
    J Urol; 2012 Sep; 188(3):741-7. PubMed ID: 22818138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decreased RECK and Increased EMMPRIN expression in urothelial carcinoma of the bladder are associated with tumor aggressiveness.
    Wittschieber D; Stenzinger A; Klauschen F; Stephan C; Jung K; Erbersdobler A; Rabien A
    Pathobiology; 2011; 78(3):123-31. PubMed ID: 21613799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate stem cell antigen predicts tumour recurrence in superficial transitional cell carcinoma of the urinary bladder.
    Elsamman E; Fukumori T; Kasai T; Nakatsuji H; Nishitani MA; Toida K; Ali N; Kanayama HO
    BJU Int; 2006 Jun; 97(6):1202-7. PubMed ID: 16686711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
    Kibar Y; Goktas S; Kilic S; Yaman H; Onguru O; Peker AF
    Ann Clin Lab Sci; 2006; 36(1):31-8. PubMed ID: 16501234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer.
    Shariat SF; Marberger MJ; Lotan Y; Sanchez-Carbayo M; Zippe C; Lüdecke G; Boman H; Sawczuk I; Friedrich MG; Casella R; Mian C; Eissa S; Akaza H; Serretta V; Huland H; Hedelin H; Raina R; Miyanaga N; Sagalowsky AI; Roehrborn CG; Karakiewicz PI
    J Urol; 2006 Sep; 176(3):919-26; discussion 926. PubMed ID: 16890655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.